These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 7611208)

  • 1. Deficiency of blood coagulation factor XIII in Crohn's disease.
    Oshitani N; Kitano A; Hara J; Suzuki N; Aoki T; Yasuda K; Watanabe Y; Obayashi M; Obata A; Nakamura S
    Am J Gastroenterol; 1995 Jul; 90(7):1116-8. PubMed ID: 7611208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of diminished factor XIII in Crohn's disease.
    Chamouard P; Grunebaum L; Wiesel ML; Sibilia J; Coumaros G; Wittersheim C; Baumann R; Cazenave JP
    Am J Gastroenterol; 1998 Apr; 93(4):610-4. PubMed ID: 9576457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of measuring blood coagulation factor XIIIA regularly and continuously in patients with Crohn's disease.
    Higaki S; Nakano K; Onaka S; Amano A; Tanioka Y; Harada K; Hashimoto S; Sakaida I; Okita K
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1407-11. PubMed ID: 16911684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healing of transsphincteric perianal fistulas in Crohn's disease using a new technique.
    Winter AM; Banks PA; Petros JG
    Am J Gastroenterol; 1993 Dec; 88(12):2022-5. PubMed ID: 8249967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report.
    van der Hagen SJ; Baeten CG; Soeters PB; Russel MG; Beets-Tan RG; van Gemert WG
    Dis Colon Rectum; 2005 Apr; 48(4):758-67. PubMed ID: 15750797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
    Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
    Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do anal fistulas in Crohn's disease behave differently and defy Goodsall's rule more frequently than fistulas that are cryptoglandular in origin?
    Coremans G; Dockx S; Wyndaele J; Hendrickx A
    Am J Gastroenterol; 2003 Dec; 98(12):2732-5. PubMed ID: 14687825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous anus and bowel operation is preferable for anal fistula in Crohn's disease.
    Shinozaki M; Koganei K; Fukushima T
    J Gastroenterol; 2002; 37(8):611-6. PubMed ID: 12203076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease.
    Korzenik JR; Dieckgraefe BK
    Aliment Pharmacol Ther; 2005 Feb; 21(4):391-400. PubMed ID: 15709989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monocytes of patients congenitally deficient in plasma factor XIII lack factor XIII subunit a antigen and transglutaminase activity.
    Muszbek L; Adány R; Kávai M; Boda Z; Lopaciuk S
    Thromb Haemost; 1988 Apr; 59(2):231-5. PubMed ID: 2898817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kallikrein-kinin system activation in Crohn's disease: differences in intestinal and systemic markers.
    Devani M; Cugno M; Vecchi M; Ferrero S; Di Berardino F; Avesani EC; de Franchis R; Colman RW
    Am J Gastroenterol; 2002 Aug; 97(8):2026-32. PubMed ID: 12190172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine.
    Egan LJ; Sandborn WJ; Tremaine WJ
    Am J Gastroenterol; 1998 Mar; 93(3):442-8. PubMed ID: 9517654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemostasis in Crohn's disease: low factor XIII levels in active disease.
    Wisén O; Gardlund B
    Scand J Gastroenterol; 1988 Oct; 23(8):961-6. PubMed ID: 3201134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies.
    Plamondon S; Ng SC; Kamm MA
    Aliment Pharmacol Ther; 2007 Mar; 25(5):557-67. PubMed ID: 17305756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of gastrostomy in patients with Crohn's disease.
    Mahajan L; Oliva L; Wyllie R; Fazio V; Steffen R; Kay M
    Am J Gastroenterol; 1997 Jun; 92(6):985-8. PubMed ID: 9177515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?
    Gaertner WB; Decanini A; Mellgren A; Lowry AC; Goldberg SM; Madoff RD; Spencer MP
    Dis Colon Rectum; 2007 Nov; 50(11):1754-60. PubMed ID: 17899271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered subjective appetite parameters in Crohn's disease patients.
    Bannerman E; Davidson I; Conway C; Culley D; Aldhous MC; Ghosh S
    Clin Nutr; 2001 Oct; 20(5):399-405. PubMed ID: 11534934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
    Niederau C; Backmerhoff F; Schumacher B; Niederau C
    Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.